J Crohns Colitis. 2023 Aug 21;17(8):1342-1353. doi: 10.1093/ecco-jcc/jjad029.

Harris A Ahmad ¹, James E East ², Remo Panaccione ³, Simon Travis ², James B Canavan ¹, Keith Usiskin ¹, Michael F Byrne ^4 5

Author information

¹Bristol Myers Squibb, Princeton, NJ, USA.

²Translational Gastroenterology Unit, Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.

³Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, AB, Canada.

⁴University of British Columbia, Division of Gastroenterology, Department of Medicine, Vancouver, BC, Canada.

⁵Satisfai Health, Vancouver, BC, Canada.

Abstract

Artificial intelligence shows promise for clinical research in inflammatory bowel disease endoscopy. Accurate assessment of endoscopic activity is important in clinical practice and inflammatory bowel disease clinical trials. Emerging artificial intelligence technologies can increase efficiency and accuracy of assessing the baseline endoscopic appearance in patients with inflammatory bowel disease and the impact that therapeutic interventions may have on mucosal healing in both of these contexts. In this review, state-of-the-art endoscopic assessment of mucosal disease activity in inflammatory bowel disease clinical trials is described, covering the potential for artificial intelligence to transform the current paradigm, its limitations, and suggested next steps. Site-based artificial intelligence quality evaluation and inclusion of patients in clinical trials without the need for a central reader is proposed; for following patient progress, a second reading using AI alongside a central reader with expedited reading is proposed. Artificial intelligence will support precision endoscopy in inflammatory bowel disease and is on the threshold of advancing inflammatory bowel disease clinical trial recruitment.